Dermatopolymyositis, unspecified type, with documented muscle involvement (myopathy). Use when the clinician has not distinguished between juvenile dermatomyositis, adult/other dermatomyositis, or polymyositis, but has confirmed myopathic manifestations.

Documentation tips

What should appear in the chart to support M33.92.

Source · Editorial brief grounded in 5 cited references ↓

• Provider must explicitly document myopathy or muscle involvement; 'myositis' or 'weakness' alone may not be sufficient to support the 'with myopathy' 5th character — get the physician to specify.
• Document the subtype if known: juvenile onset, adult/other dermatomyositis, or polymyositis each has its own subcategory; 'unspecified' should reflect a genuine diagnostic ambiguity, not a documentation gap.
• List all associated organ manifestations separately — pulmonary, dermatologic, or dysphagia complications each need their own code and are required to support MCC/CC DRG tiers.
• Capture laboratory findings that support the diagnosis (elevated CK, aldolase, myositis-specific antibodies such as anti-Jo-1) in the encounter note to substantiate medical necessity for EMG, muscle biopsy, or immunosuppressive therapy.
• Document disease activity status (active flare vs. stable vs. remission) and whether treatment includes corticosteroids, immunosuppressants, or IVIG — this affects risk stratification and downstream coding of long-term drug use (e.g., Z79.52 for long-term systemic steroid use).

Related CPT procedures

Procedure codes commonly billed with M33.92. Linking the right diagnosis to the right procedure is what establishes medical necessity.

Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis

Common coding pitfalls

The recurring mistakes coders make with M33.92 and adjacent codes.

Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓

• Using M33.92 when subtype is documented: if the note says 'adult dermatomyositis with myopathy,' the correct code is M33.12 — M33.92 is not a catch-all for dermatomyositis.
• Defaulting to M33.92 when myopathy is not documented: if organ involvement is unspecified in the note, use M33.90, not M33.92.
• Failing to code secondary manifestations such as interstitial lung disease, calcinosis, or dysphagia — these are separately reportable and affect DRG weight.
• Omitting Z79.52 (long-term use of systemic steroids) or other long-term drug codes when the patient is maintained on chronic immunosuppressive therapy.
• Confusing M33.92 (dermatopolymyositis, unspecified with myopathy) with M33.22 (polymyositis with myopathy) — polymyositis lacks the skin findings of dermatomyositis and is a distinct entity requiring separate subtype documentation.

Clinical context

Source · Editorial summary grounded in 5 cited references ↓

Sibling codes

Other billable codes under M33.9 (laterality / anatomic variants).